Veeva Systems Inc Has Another Strong Quarter, but Slower Growth Could Be on the Horizon
This earnings season, Veeva Systems (NYSE: VEEV) once again demonstrated why it has become a mainstay in the pharmaceutical industry. The company, which provides a cloud platform for companies to track everything from sales to FDA trial data, clearly has a widening moat of high switching costs protecting it.
But management's revenue forecast calls for sales to grow less than 20% for the rest of the year. That's a marked slowdown for the company, and it immediately led some to question whether or not the heady days of growth were coming to an end sooner than expected.
Image source: Getty Images.
Source: Fool.com
